Home/Imbria Pharmaceuticals/Alvin Shih, MD

AS

Alvin Shih, MD

Chief Executive Officer

Imbria Pharmaceuticals

Therapeutic Areas

Cardiovascular Metabolic Diseases

Imbria Pharmaceuticals Pipeline

Drug	Indication	Phase
Ninerafaxstat	Non-obstructive Hypertrophic Cardiomyopathy (nHCM)	Phase 2b

Leadership Team at Imbria Pharmaceuticals

Albert M. Kim, MD, PhD

Chief Medical Officer

View full Imbria Pharmaceuticals profile